ArticleJournal of the National Comprehensive Cancer Network : JNCCN2022
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Advancing Neurorehabilitation and Recovery Through Human Movement Quantification via Wearable Sensing.Neurorehabilitation and neural repair · 2026Article
- Developing the multidisciplinary and multispecialty workforce and the systems needed to sustain high-quality care from diagnosis through long-term survivorship.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- LLM-based annotation and token-augmented modeling for emotional tone classification in online cancer peer-support posts.PLOS digital health · 2026Article
- Feasibility of Using Patient Portal to Enhance Patient Engagement and Patient-Generated Data in Tertiary Hospital.Healthcare (Basel, Switzerland) · 2025Article
- Perspectives of key stakeholders on integrating wearable sensor technology into rehabilitation care: a mixed-methods analysis.Frontiers in digital health · 2025Article
- Use of Patient-Reported Outcomes in Risk Prediction Model Development to Support Cancer Care Delivery: A Scoping Review.JCO clinical cancer informatics · 2024Article
- Electronic Consent at US Cancer Centers: A Survey of Practices, Challenges, and Opportunities.JCO clinical cancer informatics · 2023Article
- Managing Critical Patient-Reported Outcome Measures in Oncology Settings: System Development and Retrospective Study.JMIR medical informatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 12 institutions in 1 country.
Funding
Abstract
backgroundCollecting, monitoring, and responding to patient-generated health data (PGHD) are associated with improved quality of life and patient satisfaction, and possibly with improved patient survival in oncology. However, the current state of adoption, types of PGHD collected, and degree of integration into electronic health records (EHRs) is unknown.
methodsThe NCCN EHR Oncology Advisory Group formed a Patient-Reported Outcomes (PRO) Workgroup to perform an assessment and provide recommendations for cancer centers, researchers, and EHR vendors to advance the collection and use of PGHD in oncology. The issues were evaluated via a survey of NCCN Member Institutions. Questions were designed to assess the current state of PGHD collection, including how, what, and where PGHD are collected. Additionally, detailed questions about governance and data integration into EHRs were asked.
resultsOf 28 Member Institutions surveyed, 23 responded. The collection and use of PGHD is widespread among NCCN Members Institutions (96%). Most centers (90%) embed at least some PGHD into the EHR, although challenges remain, as evidenced by 88% of respondents reporting the use of instruments not integrated. Forty-seven percent of respondents are leveraging PGHD for process automation and adherence to best evidence. Content type and integration touchpoints vary among the members, as well as governance maturity.
conclusionsThe reported variability regarding PGHD suggests that it may not yet have reached its full potential for oncology care delivery. As the adoption of PGHD in oncology continues to expand, opportunities exist to enhance their utility. Among the recommendations for cancer centers is establishment of a governance process that includes patients. Researchers should consider determining which PGHD instruments confer the highest value. It is recommended that EHR vendors collaborate with cancer centers to develop solutions for the collection, interpretation, visualization, and use of PGHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.